Compare Flagstar Bank NA (FLG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs ResMed Inc. — how do they compare? Flagstar Bank NA trades at $15.42 (market cap $6.26B), while ResMed Inc. trades at $201.99 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 4.6× Flagstar Bank NA's market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| FLG | RMD | |
|---|---|---|
Market Cap | $6.26B | $28.80B |
Sector | Financials | Health |
52-Week High | $15.28 | $293.73 |
52-Week Low | $10.72 | $182.82 |
Dividend Yield | 0.27% | 1.21% |
Enterprise Value | — | $27.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $15.36, up 2.67% today, with a bullish technical signal from moving averages. The stock shows improving fundamentals, with two consecutive quarterly EPS beats and a positive Q1 2026 net income. The company is executing a turnaround, highlighted by a proprietary technology transformation and a credit rating upgrade. The price trades below the consensus target of $17.05, with a price-to-book ratio of 0.82 suggesting potential undervaluation.
The outlook is cautiously optimistic, supported by analyst consensus and recent profitability. Key opportunities include continued operational improvement and capital returns. Risks involve the ongoing turnaround execution, net negative cash flow, and sensitivity to interest rates. The stock presents a value proposition if the bank sustains its recovery trajectory.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
